Managing and Treating Muscle Complications
At a Glance
Treatment for diabetes-related muscle problems depends on the cause: muscle infarction usually needs relative rest and pain relief, nerve-related muscle wasting needs pain control and rehabilitation, muscle loss needs safe exercise and nutrition, and statin problems require supervised medication changes.
Treatment for diabetic muscle issues is not “one size fits all.” Because each condition—sarcopenia, DMI, amyotrophy, and statin myopathy—has a different biological cause, the treatment approach must be tailored to the specific way the disease is behaving in your body [1][2][3].
The goal of treatment is twofold: to manage the immediate pain or weakness and to optimize your metabolic health to prevent the condition from returning or worsening [1][4]. Do not change your statin, diabetes medicines, protein intake, or exercise plan without clinical advice.
Treating Diabetic Muscle Infarction (DMI)
If you have been diagnosed with DMI (muscle tissue death from lack of blood flow), the most important treatment is often “less is more.”
- Conservative Management: The standard of care involves clinician-directed relative rest (modifying activity rather than strict prolonged bed rest, which can cause blood clots or pressure injuries), adequate pain relief (analgesia), and optimizing your blood sugar control [5][1].
- The Physical Therapy Warning: Unlike many other injuries, strenuous physical therapy should generally be deferred during the acute (initial) phase of DMI, followed by gradual mobilization as tolerated [1][6]. Stretching or exercising a muscle that is currently suffering from an infarction can actually increase your pain and delay the healing process [1].
- Antibiotics and Infection: Because DMI looks like an infection—and because an infection can sometimes coexist with an infarction—your doctor may prescribe antibiotics while they run cultures or evaluate your imaging. The decision to use antibiotics belongs to the treating clinician based on your full clinical picture, not just an MRI result [7].
- Timeline: Most patients see improvement within 6 to 8 weeks with appropriate rest and stabilization of diabetes [8].
Treating Diabetic Amyotrophy
Recovery from amyotrophy (nerve-related muscle wasting) is a marathon, not a sprint.
- Pain Relief First: The initial phase is often dominated by severe nerve pain. Doctors typically prescribe neuropathic-pain medications (like gabapentin or pregabalin) [9]. Because these medications can cause sedation or require dose adjustments for kidney function, they must be carefully monitored. Evidence for using steroids or other immunotherapies is very limited. Epidural steroid injections are not routine for this condition and can worsen your glucose control; they are generally restricted to specialist-selected circumstances [10][11].
- Intensive Rehabilitation: Once the intense pain begins to fade, physical therapy becomes the cornerstone of treatment [9]. This focuses on gait training (walking), using assistive devices like canes or walkers, and preventing muscle contractures [12][13].
- Timeline: Recovery is slow. While most people regain the ability to walk, it can take up to 18 months to reach near-normal strength [3][14].
Treating Sarcopenia (Muscle Loss)
Managing chronic muscle loss requires a combination of “fuel” and “force.”
- Resistance Training: To rebuild muscle, you need progressive resistance exercise (lifting weights or using resistance bands) at least twice a week [15][16]. Combining this with aerobic exercise (like walking or swimming) three times a week has been shown to improve strength and metabolic health in people with diabetes [17]. However, a generic minimum schedule may be unsafe. Your exercise plan must be individualized to account for hypoglycemia risk, severe neuropathy, foot ulcers, or retinopathy.
- Protein Support: You may need to increase your protein intake to a safe amount determined by your clinician. Generic high-protein targets can be dangerous if you have diabetic kidney disease. Work with a dietitian who knows your eGFR and urine albumin status to determine an individualized goal [18].
- Glucose Stability: Associations between glucose variability and muscle outcomes do not prove that targeting variability prevents sarcopenia, but keeping your blood sugar stable without risking hypoglycemia is important for overall health [19][20].
Treating Statin-Induced Issues
If your cholesterol medication is causing muscle trouble, the strategy depends on the severity. Never stop or restart a statin without the prescribing clinician’s supervision.
- The “Dechallenge” Strategy: For mild aches, your doctor may suggest a supervised plan to stop the statin temporarily to see if the pain goes away [21][22].
- The “Rechallenge” Strategy: If the pain stops, you might try a lower dose, a different type of statin, or a different schedule (like every other day) [23][22]. If statins are still not tolerated, non-statin drugs like ezetimibe or PCSK9 inhibitors may be used to maintain cardiovascular protection [24][25].
- Immunosuppression for IMNM: In the rare case of autoimmune necrotizing myopathy (IMNM), stopping the statin isn’t enough. Your body is attacking its own muscle, so you may need immunosuppressants like steroids or IVIG to stop the damage [26][27].
| Condition | Immediate Goal | Long-Term Goal | Key Treatment Tool |
|---|---|---|---|
| DMI | Pain control | Prevent recurrence | Relative rest & Sugar control [1] |
| Amyotrophy | Pain control | Mobility | Intensive Physical Therapy [12] |
| Sarcopenia | Stop muscle loss | Build strength | Resistance training & Protein [15] |
| Statin Myopathy | Confirm cause | Heart protection | Dose adjustment or Alternate drug [23] |
Common questions in this guide
What is the usual treatment for diabetic muscle infarction?
How is diabetic amyotrophy treated, and how long does recovery take?
What exercise is safe for diabetes-related muscle loss?
How much protein should I eat to rebuild muscle with diabetes?
What should I do if a statin causes muscle pain?
Does stopping a statin treat autoimmune necrotizing myopathy?
Get notified when new evidence is published on Myopathy and diabetes mellitus.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (27)
- 1
Diabetic myonecrosis: an uncommon diabetic complication.
Kempegowda P, Melson E, Langman G, et al.
Endocrinology, diabetes & metabolism case reports 2019; (2019(1)):1-4.
PMID: 32677424 - 2
Diabetic Lumbosacral Radiculoplexus Neuropathy (Diabetic Amyotrophy).
Glenn MD, Jabari D
Neurologic clinics 2020; (38(3)):553-564 doi:10.1016/j.ncl.2020.03.010.
PMID: 32703468 - 3
Diabetic amyotrophy: a painful radiculoplexus neuropathy.
Llewelyn D, Llewelyn JG
Practical neurology 2019; (19(2)):164-167 doi:10.1136/practneurol-2018-002105.
PMID: 30530723 - 4
Diabetic Myonecrosis: An Under-Recognised Complication of Poorly Controlled Diabetes with a High Morbidity- A Clinico-Radiological Study.
Kumar V, Hussain MA, Kurian ME, et al.
Indian journal of endocrinology and metabolism 2026; (30(4)):313-319 doi:10.4103/ijem.ijem_1078_25.
PMID: 42788116 - 5
Diabetic muscle infarction: a systematic review.
Horton WB, Taylor JS, Ragland TJ, Subauste AR
BMJ open diabetes research & care 2015; (3(1)):e000082 doi:10.1136/bmjdrc-2015-000082.
PMID: 25932331 - 6
Diabetic myonecrosis: An easily overlooked cause of limb pain in diabetic patients.
Wells J, Sorsby SC
Journal of the American Association of Nurse Practitioners 2024; (36(3)):194-196 doi:10.1097/JXX.0000000000000962.
PMID: 37882690 - 7
Muscle Infarction Following Rapid Glycemic Control in a Patient With Diabetes-Associated Microvascular Disease.
Boavida L, Carvalho J, Oliveira S, Delgado Alves J
Cureus 2021; (13(8)):e17182 doi:10.7759/cureus.17182.
PMID: 34540416 - 8
Spontaneous diabetic myonecrosis: report of four cases from a tertiary care institute.
Mukherjee S, Aggarwal A, Rastogi A, et al.
Endocrinology, diabetes & metabolism case reports 2015; (2015()):150003 doi:10.1530/EDM-15-0003.
PMID: 26124952 - 9
Diabetic Mononeuropathies and Diabetic Amyotrophy.
Bell DSH
Diabetes therapy : research, treatment and education of diabetes and related disorders 2022; (13(10)):1715-1722 doi:10.1007/s13300-022-01308-x.
PMID: 35969368 - 10
[Bruns Garland syndrome. Report of a case and differential diagnosis with cauda equina syndrome].
Jiménez-Ávila JM, Castañeda-Huerta JE, González-Cisneros AC
Acta ortopedica mexicana 2019; (33(1)):42-45.
PMID: 31480126 - 11
The Role of Caudal Epidural Steroid Injections in Diabetic Lumbosacral Radiculoplexus Neuropathy: A Case Report.
Roys J, Catalanatto M, Vangeison C, Husu EN
Pain medicine case reports 2022; (6(7)):267-269.
PMID: 41299949 - 12
[Lumbosacral radiculoplexus neuropathy with a small intramedullary lesion in posterior spinal cord: a case report].
Arai M
Rinsho shinkeigaku = Clinical neurology 2018; (58(12)):745-749 doi:10.5692/clinicalneurol.cn-001213.
PMID: 30487361 - 13
Lumbosacral Radiculoplexus Neuropathy: Neurologic Outcomes and Survival in a Population-Based Study.
Pinto MV, Ng PS, Howe BM, et al.
Neurology 2021; (96(16)):e2098-e2108 doi:10.1212/WNL.0000000000011799.
PMID: 33653898 - 14
Diabetic Amyotrophy (Bruns-Garland Syndrome): A Narrative Review.
Agarwal A, Srivastava MVP, Vishnu VY
Annals of Indian Academy of Neurology 2022; (25(5)):841-844 doi:10.4103/aian.aian_239_22.
PMID: 36561022 - 15
Resistance Exercise to Prevent and Manage Sarcopenia and Dynapenia.
Law TD, Clark LA, Clark BC
Annual review of gerontology & geriatrics 2016; (36(1)):205-228 doi:10.1891/0198-8794.36.205.
PMID: 27134329 - 16
Physiological mechanisms of neuromuscular impairment in diabetes-related complications: Can physical exercise help prevent it?
Lecce E, Bellini A, Greco G, et al.
The Journal of physiology 2026; (604(2)):707-734 doi:10.1113/JP287589.
PMID: 39898972 - 17
Concurrent Aerobic and Resistance Training Has Anti-Inflammatory Effects and Increases Both Plasma and Leukocyte Levels of IGF-1 in Late Middle-Aged Type 2 Diabetic Patients.
Annibalini G, Lucertini F, Agostini D, et al.
Oxidative medicine and cellular longevity 2017; (2017()):3937842 doi:10.1155/2017/3937842.
PMID: 28713486 - 18
Dietary Protein to Maintain Muscle Mass in Aging: A Case for Per-meal Protein Recommendations.
Murphy CH, Oikawa SY, Phillips SM
The Journal of frailty & aging 2016; (5(1)):49-58 doi:10.14283/jfa.2016.80.
PMID: 26980369 - 19
Glycemic variability and muscle loss in elderly type 2 diabetes: insights from continuous glucose monitoring and chest CT in 303 patients.
Zhang XL, Bai N, Mao CP, Liu CY
Frontiers in endocrinology 2026; (17()):1863226 doi:10.3389/fendo.2026.1863226.
PMID: 42440574 - 20
Association of Glucose Fluctuations with Sarcopenia in Older Adults with Type 2 Diabetes Mellitus.
Ogama N, Sakurai T, Kawashima S, et al.
Journal of clinical medicine 2019; (8(3)) doi:10.3390/jcm8030319.
PMID: 30845785 - 21
Statin-Associated Muscle Symptoms and Myotoxicity: A Clinically Oriented Narrative Review with a Practical Prevention, Evaluation, and Management Algorithm.
Epelde F
Medicina (Kaunas, Lithuania) 2026; (62(6)) doi:10.3390/medicina62061134.
PMID: 42356146 - 22
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.
Stroes ES, Thompson PD, Corsini A, et al.
European heart journal 2015; (36(17)):1012-22 doi:10.1093/eurheartj/ehv043.
PMID: 25694464 - 23
Statins, myalgia, and rhabdomyolysis.
Tournadre A
Joint bone spine 2020; (87(1)):37-42 doi:10.1016/j.jbspin.2019.01.018.
PMID: 30735805 - 24
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association.
Warden BA, Guyton JR, Kovacs AC, et al.
Journal of clinical lipidology 2023; (17(1)):19-39 doi:10.1016/j.jacl.2022.09.001.
PMID: 36115813 - 25
Diagnosis and Management of Statin-Associated Muscle Symptoms.
Cha JJ, Hong SJ
Korean circulation journal 2025; (55(11)):957-968 doi:10.4070/kcj.2025.0285.
PMID: 41044735 - 26
Statin-associated immune-mediated myopathy: biology and clinical implications.
Christopher-Stine L, Basharat P
Current opinion in lipidology 2017; (28(2)):186-192 doi:10.1097/MOL.0000000000000399.
PMID: 28207435 - 27
Challenges in Treating Statin-Associated Necrotizing Myopathy.
Webster P, Wiemer N, Al Harash A, et al.
Case reports in rheumatology 2021; (2021()):8810754 doi:10.1155/2021/8810754.
PMID: 33708450
This page explains treatment options for diabetes-related muscle complications for informational purposes only and does not replace medical advice. Do not change medicines, exercise, or protein intake without guidance from your healthcare team.